With the backing of new laws, retail pharmacists have considerable freedom to switch patients to FDA approved interchangeable biosimilars. While most are willing to use that freedom, according to a new report, unanswered questions remain.
Treating patients with rheumatic diseases often involves using biologic medications, including biosimilars.
The sixth annual National Policy & Advocacy Summit on Biologics brought together healthcare providers, policy experts, patient advocates and other stakeholders. The event exploredhow sound public policies can facilitate the expanded use of biologics in patient-centeredcare. This year’s event, held virtually, examined issues such as: Innovation and rare disease Current federal and state policy considerations […]
Health care in the United States has quietly turned a big corner. Just as the FDA approved its first interchangeable biosimilar, Oklahoma became the 50th and final state where pharmacists can substitute these lower-cost versions of biologic drugs.
I know some people who are brand loyal because they are hesitant to change. I, however, am not one of them. And I take that approach in prescribing biologics and biosimilars for my patients, too.
A new federal experiment could force tens of thousands of patients off of their medication in 2021.
The fifth annual National Policy & Advocacy Summit on Biologics brought together health care providers, policy experts, patient advocates and other stakeholders. The event explored how sound public policies can facilitate the safe use of biologics in patient-centered care. This year’s event, held virtually, examined issues such as: What the 2020 election means for health […]
I’ve never forgotten the story. It came from a man in a focus group I once conducted on irritable bowel syndrome.
Biologic medications were introduced into the United States in 1982 and biosimilar medications in 2015.
Nearly 10 years ago, Congress created a pathway for lower-cost versions of breakthrough biologic drugs.